# NERO (NCT05455424)

> Niraparib Efficacy in Patient With Unresectable Mesothelioma

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT05455424
- Phase: PHASE2
- Status: COMPLETED
- Sponsor: University Hospital Southampton NHS Foundation Trust
- Conditions: Mesothelioma, Malignant
- Interventions: Niraparib Oral Product; Active Symptom Control
- Enrollment: 88
- Primary outcome: Progression-free survival

## Commentary we found

- Podcasts: 3
- YouTube: 1

## Order

Focused, $750, price fixed at order: https://www.erudio.com/contact?report=nero-nct05455424